Olivier Humbert
About Olivier Humbert
Olivier Humbert is a Principal Scientist at Sonoma Biotherapeutics in Seattle, Washington, with over a decade of experience in genome engineering technologies, including CRISPR/Cas9. He has a strong background in viral vector gene transfer and hematopoietic stem cell gene modification, having previously worked at Fred Hutchinson Cancer Research Center and the University of Washington.
Work at Sonoma BioTherapeutics
Olivier Humbert has served as Principal Scientist at Sonoma Biotherapeutics since 2021. In this role, he focuses on advancing research in gene therapy and related fields. His work contributes to the development of innovative therapeutic applications, particularly in the area of hematopoietic stem cell gene modification. The Seattle, Washington location of Sonoma Biotherapeutics allows him to collaborate with a network of professionals in the biotechnology sector.
Previous Experience at Fred Hutchinson Cancer Research Center
Prior to joining Sonoma Biotherapeutics, Olivier Humbert worked at Fred Hutchinson Cancer Research Center for eight years, from 2013 to 2021. He held the position of Staff Scientist, where he contributed to various research initiatives. His earlier role at the same institution was as a Graduate Research Assistant from 2005 to 2010, which provided him with foundational experience in cancer research and related fields.
Educational Background
Olivier Humbert has a comprehensive educational background in biology and molecular sciences. He earned a Ph.D. in Molecular and Cell Biology from the University of Washington, where he studied from 2004 to 2010. Prior to this, he completed a B.S. in Cell and Molecular Biology at the same university from 1999 to 2001. His studies began at Lycée Koeberlé, where he achieved a B.A.C. in Earth and Life Sciences from 1992 to 1996. He also obtained a D.U.T. in Applied Biology from Université from 1996 to 1998.
Expertise in Gene Therapy and Genome Engineering
Olivier Humbert possesses proven expertise in viral vector gene transfer and in vivo gene therapy delivery. He has over a decade of experience in genome engineering technologies, particularly with CRISPR/Cas9 and base editor genome modification. His research focuses on hematopoietic stem cell gene modification and pre-clinical transplantation studies, reflecting his commitment to advancing therapeutic solutions in this area.
Research Leadership and Passion for Translational Programs
Olivier Humbert is passionate about driving ambitious translational programs and leading research groups. His experience in various research settings has equipped him with the skills necessary to manage complex projects and foster collaboration among scientists. His leadership in research initiatives aims to translate scientific discoveries into practical therapeutic applications.